tbuckley/cabot-search huggingface dataset:
1825P Prevention and prophylaxis (thromboprophylaxis - ACT) of cancer associated thrombosis (CAT) in high risk oncology patients: ACT4CAT
Authors: N.G. Tsoukalas, A.N. Christopoulou, C. Papandreou, N. Kapodistrias, A. Koumarianou, S. Peroukidis, H. Kalofonos, G.F. Samelis, C. Andreadis, A. Ardavanis, E. Samantas, A. Bokas, A. Ligdas, I. Athanasiadis, V. Barbounis, N. Kentepozidis, D. Mavroudis, A. Athanasiadis, P. Papakotoulas, I. Boukovinas
Journal: Annals of Oncology (2020)
1683P SARS-CoV-2 infection and lung cancer management in Europe
Authors: A. Agbarya, A. Addeo, A. Charpidou, A. Araújo, K. Cuppens, O.T. Brustugun, M. Rajer, M. Jakopovic, M.V. Marinca, A. Pluzanski
Journal: Annals of Oncology (2020)
650P Comparing the predictive value of exosome, circulating tumor cells, and tumor tissue in detecting AR-V7 among metastatic castration-resistant prostate cancer treated with abiraterone
Authors: S. Zhu, G. Sun, X. Zhao, J. Zhao, J. Chen, P. Shen, N. Chen, H. Zeng
Journal: Annals of Oncology (2020)
1366P Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
Authors: R. Tian, W. Guo, Y. Guo, X. Zhang, H. Zhu, F. Shen, X. Zhang, R. Wang, X. Ren, J. Li, X. Song
Journal: Annals of Oncology (2020)
1419TiP ARC-7: A phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC)
Authors: A. Chaudhry, M. Johnson, D. Colburn, H. Gilbert, A. Garofalo, M. Paoloni, K. Krishnan
Journal: Annals of Oncology (2020)
814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Authors: Y. Drew, R.T. Penson, D.M. O'Malley, J-W. Kim, S. Zimmermann, P. Roxburgh, J. Sohn, S.M. Stemmer, S. Bastian, M. Ferguson, B. You, S. Domchek, H. Gao, H. Angell, K. Meyer, L. Opincar, L. Ottesen, D.O. Koralek, S. Banerjee
Journal: Annals of Oncology (2020)

Olaparib is a PARP inhibitor approved in first-line and recurrent OC. Results of O+D in gBRCAm PSR OC have been presented. MEDIOLA (NCT02734004) then evaluated combining O+D (doublet cohort) or O+D+B (triplet cohort) in non-gBRCAm PSR OC. Here we present initial results. Pts had confirmed non-gBRCAm PSR OC and had progressed after receiving 1–2 prior lines (L) of platinum-based chemotherapy. Pts received O 300 mg bid and D 1.5g IV q4 weeks (w) and B 10 mg/kg q2w (triplet only) until progressive disease. Tumours were assessed by RECIST v1.1 at baseline and q8w. Primary endpoints were safety and 24-w disease control rate (DCR). Secondary endpoints included objective response rate (ORR), median duration of response (mDOR) and progression-free survival (PFS). From Nov 2018 to Feb 2019, 32 pts (69% 2nd L) enrolled and received O+D; from May 2018 to Jan 2019, 31 (68% 2nd L) enrolled and received O+D+B. At the data cut-off 13 Feb 2020, 22% of O+D and 42% of O+D+B pts remained on treatment. The most common grade ≥3 AEs in O+D were anaemia, lipase increased and neutropenia and anaemia, hypertension, fatigue, lipase increased, and neutropenia in O+D+B. Two (6%) and five (16%) pts discontinued one or more study drug due to an AE in O+D and O+D+B, respectively. Efficacy is summarized in the table. Efficacy in biomarker subgroups, including by presence of genome-wide loss of heterozygosity, will be presented.Table:Non-gBRCAm PSR OCDoublet cohort (O+D) n=32Triplet cohort (O+D+B) n=3124-w DCR, %28.1% (90% CI 15.5–43.9)77.4% (90% CI 61.7–88.9)Confirmed ORR, %31.3% (95% CI 16.1–50.0)77.4% (95% CI 58.9–90.4)Median confirmed DOR (mo)6.9 (IQR 5.7–11.1)11.1 (IQR 9.0–16.4)Median PFS (mo)5.5 (95% CI 3.6–7.5)14.7 (95% CI 10.0–18.1)CI, confidence interval; IQR, interquartile range. Open table in a new tab CI, confidence interval; IQR, interquartile range. Combining O+D and O+D+B was well tolerated in pts with non-gBRCAm PSR OC, consistent with the known safety profiles of the single agents. The DCR for the doublet cohort did not meet the prespecified target of 80%. The 95% CI for DCR in the triplet cohort included the prespecified target of 80%. ORR and PFS in the triplet cohort demonstrate promising activity in non-gBRCAm PSR OC, and in this group the ORR and PFS are higher than reported for single-agent PARP or VEGF inhibitors.
1048P Should I stay or should I go: Optimal duration for antiPD(L)1 therapy
Authors: J. Chen, J. Arrondeau, A. Jouinot, P. Boudou Rouquette, E. Fabre, F. Giraud, J. Chapron, O. Huillard, A. Lupo-Mansuet, D. Damotte, J. Alexandre, M. Wislez, F. Goldwasser
Journal: Annals of Oncology (2020)
750P Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)
Authors: A. Necchi, A.O. Siefker-Radtke, Y. Loriot, S.H. Park, J. Garcia-Donas, R.A. Huddart, E.F. Burgess, M.T. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Duran, Y. Zakharia, M. Fu, A. Santiago-Walker, A. O'Hagan, M. Monga, S.T. Tagawa
Journal: Annals of Oncology (2020)
Tissue-specific usage of transposable element-derived promoters in mouse development
Authors: Benpeng Miao, Shuhua Fu, Cheng Lyu, Paul Gontarz, Ting Wang, Bo Zhang
Journal: Genome biology (2020)

Abstract Background Transposable elements (TEs) are a significant component of eukaryotic genomes and play essential roles in genome evolution. Mounting evidence indicates that TEs are highly transcribed in early embryo development and contribute to distinct biological functions and tissue morphology. Results We examine the epigenetic dynamics of mouse TEs during the development of five tissues: intestine, liver, lung, stomach, and kidney. We found that TEs are associated with over 20% of open chromatin regions during development. Close to half of these accessible TEs are only activated in a single tissue and a specific developmental stage. Most accessible TEs are rodent-specific. Across these five tissues, 453 accessible TEs are found to create the transcription start sites of downstream genes in mouse, including 117 protein-coding genes and 144 lincRNA genes, 93.7% of which are mouse-specific. Species-specific TE-derived transcription start sites are found to drive the expression of tissue-specific genes and change their tissue-specific expression patterns during evolution. Conclusion Our results suggest that TE insertions increase the regulatory potential of the genome, and some TEs have been domesticated to become a crucial component of gene and regulate tissue-specific expression during mouse tissue development.
646P Prostate cancer metastatic profiles correlate with molecular alterations
Authors: O. Cussenot, E. Perrot, L. Brureau, P. Blanchet, A. Diedhiou, E. Comperat, D. Iliev, D. Pruss, K.M. Timms, G. Cancel-Tassin
Journal: Annals of Oncology (2020)
LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
Authors: X. Wu, J. Zhu, R. Yin, J. Yang, J. Liu, J. Wang, L. Wu, Z. Liu, Y. Gao, D. Wang, G. Lou, H. Yang, Q. Zhou, B. Kong, Y. Huang, L. Chen, G. Li, R. An, K. Wang, Y. Zhang
Journal: Annals of Oncology (2020)
1933MO TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
Authors: M. Palafox, L. Mina, A. Malfettone, L. Monserrat, M.J. Rodriguez, O. Rodríguez, M. Guzmán, J. Grueso, M. Scaltriti, T. Miquel, C. Saura, M. Capelán, M. Gil-Gil, A. Llombart Cussac, J. Cortés, J.M. Perez Garcia, M. Del Campo, M. Bellet Ezquerra, V. Serra
Journal: Annals of Oncology (2020)
Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study
Authors: Lars Vedel Kessing, Helene Charlotte Rytgaard, Claus Thorn Ekstrøm, Filip Krag Knop, Michael Berk, Thomas Alexander Gerds
Journal: Diabetes Care (2020)

OBJECTIVE Diabetes is associated with an increased risk of depression. Some antidiabetes agents, specifically metformin and pioglitazone, have been suggested to have beneficial effects on depression, but associations between antidiabetes drugs and depression have not been systematically investigated. RESEARCH DESIGN AND METHODS We combined four Danish population-based registers to investigate whether the 20 most widely used orally administered antidiabetes drugs were associated with an altered risk of incident depression. Analyses of insulin were included for comparisons. All persons in Denmark in 2005 were included in the study and followed until 2015. Two different outcome measures of incident depression were included: 1) a diagnosis of depressive disorder at a psychiatric hospital as an inpatient or outpatient and 2) a combined measure of a diagnosis of depression or use of antidepressants. Data were analyzed using Cox regression models. RESULTS A total of 360,205 individuals using orally administered antidiabetes drugs and 64,582 using insulin at any time during the study period were included in the analyses. Continued use of metformin and combinations of drugs including metformin were associated with decreased rates of incident depression. Pioglitazone was not associated with a decreased rate of incident depression. No other antidiabetes drugs or insulin showed significant associations with depression. CONCLUSIONS Real-life population-based data suggest a positive effect of metformin on depression rates. This evidence should be used in guiding prescriptions for patients with type 2 diabetes who are at risk for developing depression, including those with prior depression or anxiety and patients with a family history of depression.
552P Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumours
Authors: L. Shen, Y-L. Wu, Y. Yuan, Y. Bai, Q. Zhang, Q. Zhou, T. Liu, J. Zhao, S. Wang, X. Huang, H. Pan, A. Zhou, T. Sun, J. Wang, Y. Gao, S. Yang, Y. Li, J. Zhang, J. Guo
Journal: Annals of Oncology (2020)
CN9 The European Cancer Nursing Index 2020: A tool for mapping cancer nursing status across Europe
Authors: L. Sharp, H. Ullgren, M.N. Fowler, D. Protogiros, M. van Klinken, H. Hálfdánardóttir, T.A. Theologia, F. Conceicao, T. Hanan, A. Khmaladze
Journal: Annals of Oncology (2020)
Necrobiotic Xanthogranuloma on 18F-FDG PET/CT
Authors: Mohamed Eltilib, Jordan Fenner, Israel Saramago, Jorge Oldan
Journal: Clinical Nuclear Medicine (2020)

We report the case of a 57-year-old man who presented with a 6-year history of yellowish plaques on his left buttock and right medial knee, as well as ulcerating subcutaneous nodules on his forearms bilaterally. Skin biopsy, bone biopsy, and serum protein electrophoresis confirmed the diagnosis of necrobiotic xanthogranuloma with associated monoclonal gammopathy. Necrobiotic xanthogranuloma is a rare form of non-Langerhans histiocytosis characterized by development of chronic cutaneous nodules that enlarge over time to form plaques. The author discusses necrobiotic xanthogranuloma's presentation and the utility of F-FDG PET/CT in disease staging, localizing optimal biopsy sites, and assessing treatment response.
1264P Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
Authors: J. Wang, S. Lu, C. Hu, Y. Sun, K. Yang, M. Chen, J. Zhao, G. Yu, X. Zhou, G. Feng, Y. Pan, Y. Yu, J. Zhang, L. Liang, X. Lin, X. Wu, J. Cui
Journal: Annals of Oncology (2020)
466P FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis
Authors: M. Fedyanin, E. Polyanskaya, H. Elsnukaeva, A. Tryakin, I. Pokataev, S. Tjulandin
Journal: Annals of Oncology (2020)
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More <i>F508del</i> Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
Authors: Matthias Griese, Stefano Costa, Rachel W. Linnemann, Marcus A. Mall, Edward F. McKone, Deepika Polineni, Bradley S. Quon, Felix C. Ringshausen, Jennifer L. Taylor-Cousar, Nicholas J. Withers, Samuel M. Moskowitz, Cori L. Daines
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology
Authors: William F. Forrest, Bruno Alicke, Oleg Mayba, Magdalena Osinska, Michal Jakubczak, Pawel Piatkowski, Lech Choniawko, Alice Starr, Stephen E. Gould
Journal: Cancer Research (2020)

Abstract Scientists working in translational oncology regularly conduct multigroup studies of mice with serially measured tumors. Longitudinal data collected can feature mid-study dropouts and complex nonlinear temporal response patterns. Parametric statistical models such as ones assuming exponential growth are useful for summarizing tumor volume over ranges for which the growth model holds, with the advantage that the model's parameter estimates can be used to summarize between-group differences in tumor volume growth with statistical measures of uncertainty. However, these same assumed growth models are too rigid to recapitulate patterns observed in many experiments, which in turn diminishes the effectiveness of their parameter estimates as summary statistics. To address this problem, we generalized such models by adopting a nonparametric approach in which group-level response trends for logarithmically scaled tumor volume are estimated as regression splines in a generalized additive mixed model. We also describe a novel summary statistic for group level splines over user-defined, experimentally relevant time ranges. This statistic reduces to the log-linear growth rate for data well described by exponential growth and also has a sampling distribution across groups that is well approximated by a multivariate Gaussian, thus facilitating downstream analysis. Real-data examples show that this nonparametric approach not only enhances fidelity in describing nonlinear growth scenarios but also improves statistical power to detect interregimen differences when compared with the simple exponential model so that it generalizes the linear mixed effects paradigm for analysis of log-linear growth to nonlinear scenarios in a useful way. Significance: This work generalizes the statistical linear mixed modeling paradigm for summarizing longitudinally measured preclinical tumor volume studies to encompass studies with nonlinear and nonmonotonic group response patterns in a statistically rigorous manner.
1787P Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202)
Authors: Y. Liu, Y. Cheng, Q. Wang, K. Li, J. Shi, L. Wu, B. Han, G. Chen, J. He, J. Wang, H. QIN, X. Li
Journal: Annals of Oncology (2020)
1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial
Authors: F. Barlesi, M. Karimi, P. Tomasini, C. Daniel, J. Raimbourg, A-E. Quoix, A-C. Madroszyk Flandin, J. Mazieres, O. Molinier, C. Audigier-Valette, D. Moro-Sibilot, H. Morel, P-J. Souquet, I. Bieche, A. Tran-Dien, A. Jacquet, J. Adam, J-C. Soria, B. Besse
Journal: Annals of Oncology (2020)
Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization
Authors: Hironori Hara, Patrick W. Serruys, Kuniaki Takahashi, Hideyuki Kawashima, Masafumi Ono, Chao Gao, Rutao Wang, Friedrich W. Mohr, David R. Holmes, Piroze M. Davierwala, Stuart J. Head, Daniel J.F.M. Thuijs, Milan Milojevic, Arie Pieter Kappetein, Scot Garg, Yoshinobu Onuma, Michael J. Mack
Journal: Journal of the American College of Cardiology (2020)
Left Ventricular Infected Thrombus Detected by 18F-FDG PET/CT and MRI in Disseminated Staphylococcus Infection
Authors: Ana María García Vicente, Miguel Villar García, José Javier Blanch Sancho, Ángel Soriano Castrejón
Journal: Clinical Nuclear Medicine (2020)

Abstract We present the case of a 61-year-old woman with fever and acute meningitis. Clinical evaluation revealed maculopapular rash, right gluteus cellulitis, and centered retinal hemorrhages. In the intensive care unit, persistent Staphylococcus bacteremia was detected. However, transesophageal echocardiography did not reveal pathologic features. 18 F-FDG PET/CT and cardiac MRI diagnosed a left ventricular infected thrombus, an extremely rare condition especially in patients without structural cardiopathy.
1488P A prognostic biomarker study in patients who underwent surgery or received chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
Authors: K. Oshima, K. Kato, Y. Ito, H. Daiko, I. Nozaki, S. Nakagawa, Y. Shibuya, T. Kojima, Y. Toh, M. Okada, S. Hironaka, Y. Akiyama, Y. Komatsu, K. Maejima, H. Nakagawa, M. Kato, K. Kanato, A. Kuchiba, K. Nakamura, Y. Kitagawa
Journal: Annals of Oncology (2020)
Operation Moonshot proposals are scientifically unsound
Authors: Jonathan J Deeks, Anthony J Brookes, Allyson M Pollock
Journal: BMJ (2020)

The polymerase chain reaction (PCR) swab test is useful (but not perfect) for detecting SARS-CoV-2 virus RNA in symptomatic patients. 1However, problems arise using the test for purposes that disregard symptoms or time of infection-namely, case finding, mass screening, and disease surveillance.
563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study
Authors: C. Schliemann, M. Gerwing, H. Heinzow, S. Harrach, C. Schwöppe, M. Wildgruber, A. Hansmeier, L. Angenendt, A.F. Berdel, T. Kessler, C. Wilms, W. Hartmann, E. Wardelmann, T. Kraehling, W. Heindel, J. Gerss, H. Schmidt, G. Lenz, R. Mesters, W.E. Berdel
Journal: Annals of Oncology (2020)
Malignant Peripheral Nerve Sheath Tumor Arising From Transplanted Kidney Assessed by 18F-FDG PET/CT
Authors: Hongyan Feng, Ning Tu, Lihong Bu
Journal: Clinical Nuclear Medicine (2020)

Abstract Malignant peripheral nerve sheath tumor (MPNST) originates from Schwann cells or pluripotent perineural cells, which is an extremely rare tumor that occurs in the kidney. We report a case of MPNST in transplanted kidney that was diagnosed in a 32-year-old man with a history of kidney transplantation. Contrast-enhanced MRI and 18 F-FDG PET/CT features of MPNST are described, which can accurately discriminate MPNST from infection and benign tumors. These features could potentially provide valuable information to distinguish it from other renal malignancies. 18 F-FDG PET/CT may be a useful tool for the primary diagnosis and the initial staging of MPNST.
1105P Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial
Authors: P. Mohr, J. Larkin, V.F. Paly, A. Remiro Azocar, G. Baio, M. Kurt, A. Amadi, J.I. Rizzo, H.M. Johnson, A. Moshyk, S. Kotapati, M. Middleton
Journal: Annals of Oncology (2020)
Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study
Authors: Shahinaz M Gadalla, Youjin Wang, Tao Wang, Olusegun O Onabajo, A Rouf Banday, Adeola Obajemu, Ezgi Karaesman, Lara Sucheston-Campbell, Theresa Hahn, Jennifer A Sees, Stephen R Spellman, Stephanie J Lee, Hormuzd A Katki, Ludmila Prokunina-Olsson
Journal: The Lancet Haematology (2020)
Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study
Authors: Guangfu Jin, Jun Lv, Ming Yang, Mengyun Wang, Meng Zhu, Tianpei Wang, Caiwang Yan, Canqing Yu, Yanbing Ding, Gang Li, Chuanli Ren, Jing Ni, Ruoxin Zhang, Yu Guo, Zheng Bian, Yan Zheng, Nasha Zhang, Yue Jiang, Jiaping Chen, Yanong Wang, Dazhi Xu, Hong Zheng, Ling Yang, Yiping Chen, Robin Walters, Iona Y Millwood, Juncheng Dai, Hongxia Ma, Kexin Chen, Zhengming Chen, Zhibin Hu, Qingyi Wei, Hongbing Shen, Liming Li
Journal: The Lancet Oncology (2020)
1223P Genetic alterations in SWI/SNF chromatin remodeling complex in lung adenocarcinoma
Authors: M. Delgado-Ureña, M. Cuadros, P. Peinado, A. Andrades, M.I. Rodríguez, D.J. García, P.P. Medina, J.C. Villén, P. García-Villanova, F. Quero, J. López-Hidalgo, M. Gallardo, J.M. Jurado
Journal: Annals of Oncology (2020)
940P Analysis of a cohort of elderly patients (p) with head and neck cancer (HNC) managed within a multidisciplinary head and neck cancer unit (HNCU)
Authors: A. Ferrando Diez, D. Viros Porcuna, I. Teruel García, I. Planas Toledano, J. Garcia Linares, P. Cuadras Collsamata, A. Quer Pi-Sunyer, C. Viña Soria, C. Carrasco Lopez, T. Traboulsi Garet, A. Massuet Vilamajo, M.D.M. Palau Viarnes, M.J. Sendros Madroño, P. Hernandez Vergara, J. Vila Poyatos, S. Bordonaba Leiva, P. Puyalto de Pablo, J.A. Perez Gomez, B. Cirauqui Cirauqui, C. Pollan Guisasola
Journal: Annals of Oncology (2020)
1506P The predictive value of 2-D myocardial strain for epirubicin-induced cardiotoxicity
Authors: I. Ben Abdallah, S. Ben Nasr, C. Chourabi, M. Boukhris, A. Zribi, None S. Fendri, M. Balti, None W. Fehri, N. Chraiet, A. Haddaoui
Journal: Annals of Oncology (2020)
Cancer Biomarkers and Big Data: A Planetary Science Approach
Authors: Daniel J. Crichton, Alphan Altinok, Christopher I. Amos, Kristen Anton, Luca Cinquini, Maureen Colbert, Ziding Feng, Ajay Goel, Sean Kelly, Heather Kincaid, David Liu, Santiago Lombeyda, Ashish Mahabal, Asitang Mishra, Christos Patriotis, Sudhir Srivastava
Journal: Cancer Cell (2020)
1035P Effect of gut microbiota on immunotherapy of advanced NSCLC
Authors: F. Zhang, N. Dong, M. Ferrero Gimeno, S. Calabuig-Fariñas, S. Gallach, A. Blasco Cordellat, F.D.A. Aparisi Aparisi, M. Meri Abad, C. García González, G. D'Auria, R. Sirera Perez, E. Jantus Lewintre, C.J.C. Camps Herrero
Journal: Annals of Oncology (2020)
463P The prognostic role of tumour inflammation markers in patients (pts) with colorectal cancer (CRC) treated with trifluridine/tipiuracil hydrochloride: Real-world data (RWD) from Greater Manchester
Authors: A. Alchawaf, M. Dawood, M. Al-Ani, A. Ho, A. Ferrera, M. Saunders, N. Tinsley, M. Nasralla, N. Paton, G. Wilson, M. Braun, N. Alam, J.H. Hasan, F. Marti Marti, K. Kamposioras, S. Mullamitha, J. Barriuso
Journal: Annals of Oncology (2020)
486P Genetic polymorphism profile associated with cetuximab efficiency in colorectal cancer patients from Kazakhstan
Authors: I. Kadyrova, D. Babenko, S. Kolesnichenko, Y. Kolesnikova, A. Turmukhambetova, L. Akhmaltdinova, I. Korshukov, V. Sirota, V. Zhumaliyeva, D. Tayzhanova
Journal: Annals of Oncology (2020)